DNCB Patch for Early HIV Infection: Immunologic Parameters and HIV RNA Monitoring
Dinitrochlorobenzene
Blood-Borne Infections+11
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This study focuses on early HIV infection and the potential benefits of a treatment called dinitrochlorobenzene (DNCB). The main goal is to see how well DNCB works in people who have HIV, by keeping track of their immune system responses and the amount of HIV in their blood. The study aims to provide a better understanding of how HIV affects the immune system, which could help in developing more effective treatments in the future.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.46 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 55 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Patients must have: EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests. For HIV+ patients: Patients must fail to meet the AIDS-defining criteria. CD4 lymphocyte count between 200 - 500 cells/mm3. Exclusion Criteria Co-existing Condition: Excluded: Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites. Concurrent Medication: Excluded: Patients who are likely to commence antiretrovirals within the 6-month study period. Patients using other immunomodulator therapies or other alternative therapies. Patients likely to require chemotherapy during the course of the study. Concurrent Treatment: Excluded: Patients who are likely to require significant UV light exposure during the study period. Patients who are likely to require radiation therapy during the course of the study. Prior Medication: Excluded: Prior exposure to DNCB. Patients who have used antiretroviral medications within the previous 3 months.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Queen Emma Clinics / The Queen's Med Ctr
Honolulu, United StatesOpen Queen Emma Clinics / The Queen's Med Ctr in Google Maps